Abstract

Background: The mechanism of miR-320d in EGFR-positive colorectal cancer (CRC) has not been fully elucidated. The aim of the present study was to explore the molecular mechanism of miR-320d in CRC. Methods: The miRNA microarray analysis was conducted to identify differential expressed miRNAs. The expression of miR-320d was validated using quantitative real-time PCR. EGFR-positive CRC cells were transfected with miR-320d mimic and inhibitor, after which cell proliferation, migration, and invasion were assayed. The relationship between miR-320d and TUSC3 was confirmed using bioinformatics and dual-luciferase reporter gene assays. Proteins involved in signaling pathways and the epithelial–mesenchymal transition were detected with Western blot. Results: We found that the miR-320d expression is associated with tumor size and distant metastasis in colorectal cancer. Overexpression of miR-320d in EGFR-positive HCT-116 and SW480 cells decreased not only the proliferation ability but also the invasion and migration ability. In addition, miR-320d had the ability to inhibit epithelial-to-mesenchymal transition. Luciferase assays revealed that miR-320d directly targets the 3′-UTR of TUSC3. TUSC3 was downregulated by miR-320d at both the protein and mRNA levels in EGFR-positive CRC cell lines. Conclusion: Generally, our results demonstrated that miR-320d could inhibit the malignant phenotype of EGFR-positive CRC through targeting TUSC3. The miR-320d might be a potential therapeutic target for EGFR-positive CRC.

Highlights

  • BACKGROUNDColorectal cancer (CRC) is the second leading cause of cancer death worldwide (Bray et al, 2018)

  • Early-stage colorectal cancer (CRC) can be ideally treated by radical surgical resection, while advanced CRC is usually treated by a combination of surgery and chemotherapy, but miR-320d Inhibits CRC

  • Overexpression of Tumor-suppressor candidate 3 (TUSC3) largely reversed the inhibitory effect of miR-320d on invasion (Figure 5A) and proliferation (Figure 5B) of CRC cells. These results suggest that miR-320d inhibits the malignant phenotype of epidermal growth factor receptor (EGFR)-positive CRC cell which is mediated by TUSC3

Read more

Summary

Introduction

BACKGROUNDColorectal cancer (CRC) is the second leading cause of cancer death worldwide (Bray et al, 2018). Early-stage CRC can be ideally treated by radical surgical resection, while advanced CRC is usually treated by a combination of surgery and chemotherapy, but miR-320d Inhibits CRC postoperative recurrence and uncontrollable metastasis of tumor cells are among the most important causes of death in CRC patients (Zhang et al, 2021). More than 90% of CRC patients overexpress EGFR, so it is necessary to further explore the molecular biological mechanism of EGFR-positive CRC and identify more precise biomarkers to improve the effectiveness of individualized treatment strategies (Morgan et al, 2018). The mechanism of miR-320d in EGFR-positive colorectal cancer (CRC) has not been fully elucidated. The aim of the present study was to explore the molecular mechanism of miR-320d in CRC

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call